From executive to financier
29.06.2015 - Ex-Sanofi-CEO Christopher Viehbacher has been named Managing Partner of Waypoint Capital’s Gurnet Point Capital fund worth US$2bn.
Waypoint Capital is the business enterprise for investments associated with the Bertarelli family. The fund managed by Viehbacher will have an initial allocation of US$2bn (€1.8bn) of capital to invest, with a mandate to lead its global healthcare investment strategy.
“We have considerable capital to invest, but to succeed in the healthcare market requires more than money; it requires the experience, ability and relationships to create successful partnerships; the development and regulatory competency; and the know-how to create value from individual molecules, devices or technologies,” commented Ernesto Bertarelli, Chairman of Waypoint. “[Viehbacher] has these qualities in abundance.”
Viehbacher was abruptly removed from his role of Sanofi’s Chief Executive Officer by the board of directors on 29 October last year. He had been at the helm of the French drugmaker for six years, and had frequently clashed with the board of directors.
With his dismissal at Sanofi, he also laid down his roles as chairman of Genzyme and, shortly after, his position as president of pharmaceutical business association EFPIA.http://www.european-biotechnology-news.com/people/bio-people/2015/chris-viehbacher.html